LOBULAR CARCINOMA IN SITU
Clinical trials for LOBULAR CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new LOBULAR CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for LOBULAR CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug shrink precancerous breast cells before surgery?
Disease control CompletedThis study tested whether a drug called ruxolitinib can reduce abnormal breast cells in people with high-risk or precancerous breast conditions like DCIS or atypical hyperplasia. Half of the 84 participants took ruxolitinib for about 15 days before surgery, and the other half too…
Matched conditions: LOBULAR CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Julie Nangia • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Baby tamoxifen shows promise in preventing breast cancer recurrence
Prevention CompletedThis study follows up on women who took a low dose of tamoxifen (5 mg daily) for three years to see if it continues to prevent breast cancer over the long term. The original trial found a 42% reduction in breast cancer events. Researchers will also combine data from three similar…
Matched conditions: LOBULAR CARCINOMA IN SITU
Sponsor: Ente Ospedaliero Ospedali Galliera • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC
-
New study tests skills training to help breast cancer survivors overcome Long-Term pain
Symptom relief CompletedThis study tested two behavioral programs—coping skills training and general health education—to see which better improves well-being in people with ongoing pain after breast cancer surgery. About 316 participants who had surgery for breast cancer or precancerous conditions took …
Matched conditions: LOBULAR CARCINOMA IN SITU
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC